Severe and Late Acute Liver Injury Induced by Capecitabine

被引：5

作者：

Habib, Mhd Baraa ^{[1
]}

Hanafi, Ibrahem ^{[2
]}

Alzoubi, Maya ^{[2
]}

Bdeir, Zeina ^{[2
]}

Yassin, Mohamed A. ^{[3
]}

机构：

[1] Hamad Med Corp, Internal Med, Doha, Qatar

[2] Damascus Univ, Fac Med, Internal Med, Damascus, Syria

[3] Hamad Med Corp, Hematol, Doha, Qatar

来源：

CUREUS JOURNAL OF MEDICAL SCIENCE | 2021年 / 13卷 / 01期

关键词：

capecitabine; severe hepatotoxicity; late acute liver injury; colon cancer; reversible adverse effect;

D O I：

10.7759/cureus.12477

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

Capecitabine (CAP) is an antineoplastic agent that is known to cause mild hepatotoxicity. However, severe and late acute liver injury was not reported previously as an adverse reaction of CAP. This report discusses the case of a 63-year-old man with colon cancer who was receiving the fifth cycle of CAP as a monotherapy and presented with fatigue and jaundice during the fifth cycle of CAR Laboratory tests showed markedly elevated transaminases (aspartate transaminase: 2,448 U/L; alanine transaminase: 1,984 U/L). Eventually, discontinuation of CAP was enough to reverse the delayed CAP-induced acute hepatic injury in clinical and laboratory terms.

引用

页数：3

共 10 条

[1]

[Anonymous], 2012, LiverTox: Clinical and Research Information on Drug-Induced Liver Injury

[2]

[Anonymous], 2019, XELODA CAPECITABINE

[3] Hepatotoxicity by Drugs: The Most Common Implicated Agents [J].

Bjornsson, Einar S. .

INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2016, 17 (02)

[4] Cancer Incidence in Five Continents: Inclusion criteria, highlights from Volume X and the global status of cancer registration [J].

Bray, F. ;

Ferlay, J. ;

Laversanne, M. ;

Brewster, D. H. ;

Mbalawa, C. Gombe ;

Kohler, B. ;

Pineros, M. ;

Steliarova-Foucher, E. ;

Swaminathan, R. ;

Antoni, S. ;

Soerjomataram, I. ;

Forman, D. .

INTERNATIONAL JOURNAL OF CANCER, 2015, 137 (09) :2060-2071

[5] Features and Outcomes of 899 Patients With Drug-Induced Liver Injury: The DILIN Prospective Study [J].

Chalasani, Naga ;

Bonkovsky, Herbert L. ;

Fontana, Robert ;

Lee, William ;

Stolz, Andrew ;

Talwalkar, Jayant ;

Reddy, K. Rajendar ;

Watkins, Paul B. ;

Navarro, Victor ;

Barnhart, Huiman ;

Gu, Jiezhun .

GASTROENTEROLOGY, 2015, 148 (07) :1340-+

[6] Hepatic steatosis secondary to capecitabine: A case report [J].

Chin S. ;

Kim T. ;

Siu L. .

Journal of Medical Case Reports, 4 (1)

[7] Liver enzyme alteration: a guide for clinicians [J].

Giannini, EG ;

Testa, R ;

Savarino, V .

CANADIAN MEDICAL ASSOCIATION JOURNAL, 2005, 172 (03) :367-379

[8]

Hirsch Bradford R, 2011, Cancer Manag Res, V3, P79, DOI 10.2147/CMR.S11250

[9] Hepatic Histological Findings in Suspected Drug-Induced Liver Injury: Systematic Evaluation and Clinical Associations [J].

Kleiner, David E. ;

Chalasani, Naga P. ;

Lee, William M. ;

Fontana, Robert J. ;

Bonkovsky, Herbert L. ;

Watkins, Paul B. ;

Hayashi, Paul H. ;

Davern, Timothy J. ;

Navarro, Victor ;

Reddy, Rajender ;

Talwalkar, Jayant A. ;

Stolz, Andrew ;

Gu, Jiezhun ;

Barnhart, Huiman ;

Hoofnagle, Jay H. .

HEPATOLOGY, 2014, 59 (02) :661-670

[10]

Saif MW, 2008, ANTI-CANCER DRUG, V19, P447, DOI 10.1097/CAD.0b013e3282f945aa

← 1 →